SMSbiotech Founder Discusses Inhaled Stem Cell Therapy for COPD in MIA Interview
SMSbiotech is proud to share that Dr. Abdulkader Rahmo, our Co‑Founder and Chief Scientific Officer, was recently interviewed by MIA (Media Information Agency) following their interest in potential treatments for patients in Europe, Macedonia, and worldwide using our Small Mobile Stem Cells platform. (mia.mk)
In the interview, Dr. Rahmo explained how these unique, tiny stem cells are derived from healthy donor blood, nebulized into a mist, and inhaled into the lungs where they stimulate the patient’s own cells to regenerate alveoli and healthy lung tissue. He highlighted the progress of clinical development, including Phase 1 trials in Australia and plans for Phase 2 in the U.S., and discussed the potential application for other conditions such as osteoarthritis, lung fibrosis, and gangrene
Dr. Rahmo also shared optimism about regulatory pathways, including compassionate use programs for patients with serious conditions prior to full approval, emphasizing the importance of early access for patients in need.
Read the full interview on MIA: Exclusive interview for MIA with Abdulkader Rahmo on curing currently incurable emphysema by merely inhaling stem cells. (mia.mk)
